Neil Klompas - Zymeworks Common President
| ZYME Stock | USD 13.95 0.55 3.79% |
President
Mr. Neil Klompas is Chief Financial Officer of the Company. Mr. Klompas brings over 20 years of healthcare and biotechnology experience to our management team. In addition to finance responsibilities, and in conjunction with our President and Chief Executive Officer, he manages our corporate growth initiatives. Prior to joining Zymeworks Inc. in March 2007, he worked with KPMG LLP in Canada and the United States, most recently with KPMGs Pharmaceuticals, Biotechnology and Medical Device MA Transaction Services practice in Princeton, New Jersey, where he advised on numerous transactions including mergers, acquisitions, divestitures and strategic alliances. Prior to that, from 2000 to 2005 Mr. Klompas worked with KPMGs Canadian Biotechnology and Pharmaceuticals practice in the fields of assurance, valuations and taxation. Mr. Klompas is a Chartered Professional Accountant and is a member of Chartered Professional Accountants of British Columbia. Mr. Klompas also holds a degree in Microbiology Immunology from the University of British Columbia and serves on the faculty advisory board for Biotechnology and Chemistry for Camosun College and as a Director for the Canadian Gene Cure Foundation. since 2022.
| Age | 49 |
| Tenure | 2 years |
| Address | 108 Patriot Drive, Middletown, DE, United States, 19709 |
| Phone | 302 274 8744 |
| Web | https://www.zymeworks.com |
Neil Klompas Latest Insider Activity
Tracking and analyzing the buying and selling activities of Neil Klompas against Zymeworks Common stock is an integral part of due diligence when investing in Zymeworks Common. Neil Klompas insider activity provides valuable insight into whether Zymeworks Common is net buyers or sellers over its current business cycle. Note, Zymeworks Common insiders must abide by specific rules, including filing SEC forms every time they buy or sell Zymeworks Common'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Neil Klompas over a year ago Exercise or conversion by Neil Klompas of 2500 shares of Zymeworks subject to Rule 16b-3 |
Zymeworks Common Management Efficiency
The company has return on total asset (ROA) of (0.1469) % which means that it has lost $0.1469 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2873) %, meaning that it created substantial loss on money invested by shareholders. Zymeworks Common's management efficiency ratios could be used to measure how well Zymeworks Common manages its routine affairs as well as how well it operates its assets and liabilities. As of December 4, 2024, Return On Tangible Assets is expected to decline to -0.23. In addition to that, Return On Capital Employed is expected to decline to -0.28. At present, Zymeworks Common's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Intangibles To Total Assets is expected to grow to 0.12, whereas Non Currrent Assets Other are forecasted to decline to about 5.3 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Erin MD | Terns Pharmaceuticals | 53 | |
| Mark Smythe | Protagonist Therapeutics | 59 | |
| Ashish Mandelia | Mersana Therapeutics | 49 | |
| Christopher Murray | Blueprint Medicines Corp | 61 | |
| Calvin Yu | Alector | 48 | |
| Saraswati KenkareMitra | Alector | 56 | |
| Robert Wong | Cytokinetics | 56 | |
| Ashok Bhandari | Protagonist Therapeutics | 60 | |
| Ching Jaw | Cytokinetics | 61 | |
| Meredith Kaya | Apellis Pharmaceuticals | N/A | |
| Cameron MBA | Zentalis Pharmaceuticals Llc | 54 | |
| Neil MD | Syndax Pharmaceuticals | 60 | |
| Fouad MD | Blueprint Medicines Corp | 55 | |
| Victoria Brown | Apellis Pharmaceuticals | 44 | |
| Joris Wilms | Y mAbs Therapeutics | 50 | |
| Gwendolyn Binder | Cabaletta Bio | 49 | |
| Brian DeSchuytner | Mersana Therapeutics | 46 | |
| Sara KenkareMitra | Alector | 56 | |
| Suneel Gupta | Protagonist Therapeutics | 66 | |
Management Performance
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.15 |
Zymeworks Common Stock Leadership Team
Elected by the shareholders, the Zymeworks Common's board of directors comprises two types of representatives: Zymeworks Common inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zymeworks. The board's role is to monitor Zymeworks Common's management team and ensure that shareholders' interests are well served. Zymeworks Common's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zymeworks Common's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jack Spinks, Associate Relations | ||
| Neil MD, Chief Officer | ||
| Mark Hollywood, Executive Operations | ||
| Neil Josephson, Interim Chief Medical Officer | ||
| Anthony Polverino, Executive Vice President - Early Development, Chief Scientific Officer | ||
| Christopher Astle, Chief Financial Officer, Senior Vice President | ||
| Thomas Kreudenstein, Director Engineering | ||
| Paul Moore, Chief Officer | ||
| Diana Papove, Senior Communications | ||
| Jeffrey MD, Executive Officer | ||
| Diana Hausman, Chief Medical Officer | ||
| Nina Weisser, Director Therapeutics | ||
| Kenneth Galbraith, Chairman of the Board, President, Chief Executive Officer | ||
| Leone MBA, EVP CFO | ||
| Ryan Dercho, Senior Affairs | ||
| Lota Zoth, Lead Independent Director | ||
| Kenneth CA, CEO Chairman | ||
| Daniel JD, Corporate VP | ||
| Lindsey BSc, Vice Development | ||
| Shrinal Inamdar, Director Relations | ||
| Ali Tehrani, President, Chief Executive Officer, Co-Founder, Director | ||
| Neil Klompas, Chief Financial Officer, Executive Vice President - Business Operations | ||
| Josemund MBBS, Managing Pacific | ||
| Laura OConnor, Head Resources | ||
| John Fann, Senior Sciences | ||
| David Poon, VP Management |
Zymeworks Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zymeworks Common a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (1.83) % | ||||
| Operating Margin | (2.14) % | ||||
| Current Valuation | 721.77 M | ||||
| Shares Outstanding | 68.88 M | ||||
| Shares Owned By Insiders | 0.08 % | ||||
| Shares Owned By Institutions | 99.92 % | ||||
| Number Of Shares Shorted | 4.21 M | ||||
| Price To Earning | (2.36) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Zymeworks Common Stock is a strong investment it is important to analyze Zymeworks Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zymeworks Common's future performance. For an informed investment choice regarding Zymeworks Stock, refer to the following important reports:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zymeworks Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zymeworks Common. If investors know Zymeworks will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zymeworks Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.49) | Revenue Per Share 0.831 | Quarterly Revenue Growth (0.03) | Return On Assets (0.15) | Return On Equity (0.29) |
The market value of Zymeworks Common Stock is measured differently than its book value, which is the value of Zymeworks that is recorded on the company's balance sheet. Investors also form their own opinion of Zymeworks Common's value that differs from its market value or its book value, called intrinsic value, which is Zymeworks Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zymeworks Common's market value can be influenced by many factors that don't directly affect Zymeworks Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zymeworks Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zymeworks Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zymeworks Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.